Bristol Myers Squibb Co. on Wednesday said its third-quarter sales rose 10 percent and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.
The New York-based drugmaker’s revenue for the quarter of $11.6 billion and adjusted profit of $2.00 per share both topped Wall Street estimates of $11.58 billion in sales and $1.92 per share, according to IBES data from Refinitiv.
